LIST OF PUBLICATIONS

- **Original papers:**

1. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
   Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, **Calcinotto A**, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. **J Clin Invest. 2020** Apr 6. pii: 131133. doi: 10.1172/JCI131133
   https://pubmed.ncbi.nlm.nih.gov/32250342/

2. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
   Di Mitri D, Mirenda M, Vasilevska J, **Calcinotto A,** Delaleu N, Revandkar A, Gil V, Boysen G, Losa M, Mosole S, Pasquini E, D'Antuono R, Masetti M, Zagato E, Chiorino G, Ostano P, Rinaldi A, Gnetti L, Graupera M, Martins Figueiredo Fonseca AR, Pereira Mestre R, Waugh D, Barry S, De Bono J, Alimonti A. **Cell Rep. 2019** Aug 20;28(8):2156-2168.e5. doi: 10.1016/j.celrep.2019.07.068.
   https://pubmed.ncbi.nlm.nih.gov/31433989/

3. **IL23 secreted by myeloid cells drives castration-resistant prostate cancer.**
   Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros M.B., Neeb A., Lucianò R., Bravi C.A., Nava-Rodrigues D., Dolling D., Prayer-Galetti T., Ferreira A., Briganti A., Esposito A., Barry S., Yuan W., Sharp A., de Bono J & Alimonti A. **Nature 2018** doi:10.1038/s41586-018-0266-0.
   https://www.ncbi.nlm.nih.gov/pubmed/29950727

4. **Commensal bacteria accelerate multiple myeloma progression by inducing interleukin-17-producing cells.**
   Calcinotto A, Chesi M, Brevi A, Ferrarese R, Kumar S, Grioni M, Henderson KJ, Tonon G, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M. **Nature commun 2018** Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.
   https://www.ncbi.nlm.nih.gov/pubmed/30510245

5. Biomodal CD40/Fas-Dependent Crosstalk between iNKT cells and Tumor-Associated Macrophages impairs prostate cancer progression
   Cortesi F, Delfanti G, Grilli A, **Calcinotto A**, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Bicciato S, Doglioni C, Bellone M, Casorati G, Dellabona P. **Cell Rep. 2018** Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058
   https://www.ncbi.nlm.nih.gov/pubmed/29539427

6. IAP antagonists induce anti-tumor immunity in multiple myeloma.
   Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, **Calcinotto A**, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL.
   Nat Med. 2016 Dec;22(12):1411-1420. doi: 10.1038/nm.4229. Epub 2016 Nov 14
   https://www.ncbi.nlm.nih.gov/pubmed/27841872

7. Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.
Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, **Calcinotto A**, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.
Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11
https://www.ncbi.nlm.nih.gov/pubmed/26869462

8. Targeting vasculogenesis to prevent progression in multiple myeloma.
Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, **Calcinotto A**, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM.
Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.
https://www.ncbi.nlm.nih.gov/pubmed/26859080

9. **Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.**
Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Bertilaccio MTS, Chesi M, Rubinacci A, Tonon G, Bergsagel P. L, Vacca A, Bellone M.
Oncoimmunology. 2015 May 7;4(6):e1008850. eCollection 2015 Jun.
https://www.ncbi.nlm.nih.gov/pubmed/26155424

10. Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.
Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, **Calcinotto A**, Freschi M, Bachi A, Galli R, Bellone M.
Cancer Res. 2015 Mar 25.
https://www.ncbi.nlm.nih.gov/pubmed/25808872

11. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.
Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, **Calcinotto A**, Freschi M, Mondino A, Galli R, Bellone M.
OncoImmunology. 2013 May 1;2(5):e24520.
https://www.ncbi.nlm.nih.gov/pubmed/23762811

12. **Modulation of microenvironment acidity reverses anergy in human and murine tumour-infiltrating T lymphocytes.**
Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L. **Cancer Res. 2012** Jun 1;72(11):2746-56.
https://www.ncbi.nlm.nih.gov/pubmed/22593198

13. **Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumours and increases the therapeutic potential of immunotherapy.**
Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M.
J Immunol. 2012 Mar 15;188(6):2687-94.
https://www.ncbi.nlm.nih.gov/pubmed/22323546

14. iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.
Bellone M, Ceccon M, Grioni M, Jachetti E, **Calcinotto A**, Napolitano A, Freschi M, Casorati G, Dellabona P.

PLoS One. 2010 Jan 13;5(1):e8646.
https://www.ncbi.nlm.nih.gov/pubmed/20072624

- **Original papers under revision:**

i. Commensal bacteria promote endocrine-resistance in prostate cancer via androgen biosynthesis
Calcinotto A., Zagato E, Pernigoni N, Troiani M, Pereira Mestre R, Attanasio G, Troisi J, Minini M, et al. Jobin C, Rescigno M, Gillessen S, de Bono J & Alimonti A.
Nature *Under Revision*

ii. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy
Montopoli M, Zorzi M, Cocetta V, Prayer-Galetti T, Guzzinati S, Bovo E, Rugge E., **Calcinotto A.**
Annals of Oncology *Under Revision*

iii. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism
Grioni M, Brevi A, Cattaneo E, Rovida A, Bertilaccio MTS, Ponzoni M, Caligaris-Cappio F, Casorati G, Dellabona P, Ghia P, Bellone M, **Calcinotto A.**
Blood Adv *Under Revision*

- **Review:**

15. **Cellular Senescence in Aging, Cancer and Injury**
Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A.
Physiological Review 2019 Apr 1;99(2):1047-1078. doi: 10.1152/physrev.00020.2018.
https://www.ncbi.nlm.nih.gov/pubmed/30648461

16. Aging tumor cells to cure cancer: "Pro-senescence" therapy for cancer
Calcinotto A, Alimonti A. **Swiss Med Wkly. 2017** Jan 19;147:w14367. doi: 10.4414/smw.2017.14367. eCollection 2017 Jan 19.
https://www.ncbi.nlm.nih.gov/pubmed/28102876

17. Boosting anticancer vaccines: Too much of a good thing?
Ricupito A, Grioni M, **Calcinotto A**, Bellone M.
OncoImmunology. 2013 Jul 1;2(7):e25032.
https://www.ncbi.nlm.nih.gov/pubmed/24073378

18. Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes.
Bellone M, **Calcinotto A.**
Front Oncol. 2013 Sep 11;3:231. Review
https://www.ncbi.nlm.nih.gov/pubmed/24062984

19. Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings.
Ricupito A, Grioni M, **Calcinotto A**, Hess Michelini R, Longhi R, Mondino A, Bellone M.
Cancer Res. 2013 Jun 15;73(12):3545-54
https://www.ncbi.nlm.nih.gov/pubmed/23539449

20. The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors.

Bellone M, **Calcinotto A**, Filipazzi P, De Milito A, Fais S, Rivoltini L.
OncoImmunology. 2013 Jan 1;2(1):e22058.
https://www.ncbi.nlm.nih.gov/pubmed/23483769

21. Won't you come on in? How to favor lymphocyte infiltration in tumors.
Bellone M, **Calcinotto A**, Corti A.
OncoImmunology. 2012 Sep 1;1(6):986-988.
https://www.ncbi.nlm.nih.gov/pubmed/23162781

PATENTS

US 62/734,002 "Enhancement of Prostate Cancer Treatment"

EP 18 209 623.0. "Bacterial strains for medical uses"